• Aline Fastrès, Florence Felice, Elodie Roels, Catherine Moermans, Jean-Louis Corhay, Fabrice Bureau, Renaud Louis, Cécile Clercx, and Julien Guiot.
• Department of Clinical Sciences, FARAH, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium. afastres@uliege.be.
• Int J Mol Sci. 2017 Dec 16; 18 (12).

AbstractThis review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF.

16 keywords...

hide…